Peapod Lane Capital LLC Makes New Investment in Assembly Biosciences, Inc. (NASDAQ:ASMB)

Peapod Lane Capital LLC bought a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 62,970 shares of the biopharmaceutical company’s stock, valued at approximately $994,000.

Separately, JPMorgan Chase & Co. grew its position in shares of Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 3,442 shares during the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $12.57 on Thursday. Assembly Biosciences, Inc. has a 12 month low of $11.01 and a 12 month high of $19.93. The stock has a fifty day moving average price of $15.12 and a 200 day moving average price of $15.68.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Insider Activity

In other news, Director Michael Houghton acquired 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now directly owns 3,202 shares in the company, valued at approximately $49,983.22. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Assembly Biosciences Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.